Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Eduardo Diaz‐Rubio"'
Publikováno v:
Molecular Oncology, Vol 15, Iss 3, Pp 801-808 (2021)
Traditionally, the prevention of cancer (and other chronic diseases) has been considered primarily linked to personal responsibility, for which interventions must be based on health education information enabling individuals to make knowledge‐based
Externí odkaz:
https://doaj.org/article/f273c5486b4f4a71aca7544ddb2c7d02
Autor:
Lorena Martin-Morales, Paula Rofes, Eduardo Diaz-Rubio, Patricia Llovet, Victor Lorca, Inmaculada Bando, Pedro Perez-Segura, Miguel de la Hoya, Pilar Garre, Vanesa Garcia-Barberan, Trinidad Caldes
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0203885 (2018)
Half of the high-risk colorectal cancer families that fulfill the clinical criteria for Lynch syndrome lack germline mutations in the mismatch repair (MMR) genes and remain unexplained. Genetic testing for hereditary cancers is rapidly evolving due t
Externí odkaz:
https://doaj.org/article/4a704019a31a48e69de715f4072826db
Autor:
GLORIA MARQUINA, ARANZAZU MANZANO, CELINA BENAVENTE, NATALIA PEREZ MACIAS, ANA RIVAS, EDUARDO DIAZ-RUBIO, ANTONIO CASADO
Publikováno v:
Cancer Diagn Progn
Background/Aim: In patients with advanced platinum-resistant ovarian cancer we prospectively evaluated whether trabectedin could resensitize the tumor cells to platinum rechallenge. Patients and Methods: Upon progression to platinum-based chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c00ff41493dbd8ccb3bb017ea0e68d94
https://europepmc.org/articles/PMC10165368/
https://europepmc.org/articles/PMC10165368/
Autor:
Tania Calvo-López, Mateo Paz-Cabezas, Patricia Llovet, Maria Dolores Ibañez, Javier Sastre, Vicente Alonso-Orduña, J.Ma. Viéitez, Alfonso Yubero, Ruth Vera, Elena Asensio-Martínez, Pilar Garcia-Alfonso, Enrique Aranda, Eduardo Diaz-Rubio, Beatriz Perez-Villamil
Publikováno v:
Cancer Biomarkers. 34:201-210
BACKGROUND: MicroRNAs (miRs) are frequently altered in colorectal cancer (CRC) and can be used as prognostic factors. OBJECTIVE: To confirm in stage III CRC patients a reported miR signature that was associated to the presence of metastatic disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b6c331dacb6610f1378c7b21ade693
https://doi.org/10.3233/cbm-210353
https://doi.org/10.3233/cbm-210353
Autor:
Kaitlyn K.H. Goey, Harpreet Wasan, Aimery de Gramont, Benoist Chibaudel, Tim Maughan, Axel Hinke, Roberto Labianca, Cornelis J A Punt, Kjell Magne Tveit, Susanna Hegewisch-Becker, Louise J. Brown, David E. Fisher, Richard Kaplan, Richard Adams, Eduardo Diaz Rubio, Dirk Arnold, Miriam Koopman
Publikováno v:
Cancer treatment reviews. 99
Background\ud Intermittent systemic anti-cancer therapy in patients with advanced colorectal cancer (aCRC) may improve quality of life without compromising overall survival (OS). We aimed to use individual patient data meta-analysis (IPDMA) from mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64d0a39b4f5afcf94ef0cb267f0ef019
http://www.scopus.com/inward/record.url?scp=85107814950&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85107814950&partnerID=8YFLogxK
Autor:
Jun Yin, Matthew T. Seymour, Axel Grothey, Aimery de Gramont, Thierry André, Eduardo Diaz Rubio, Benoist Chibaudel, Alfredo Falcone, Heinz-Josef Lenz, Eric Van Cutsem, Volker Heinemann, Cornelis J A Punt, Zhaohui Jin, Tim Maughan, Richard Kaplan, Romain Cohen, Richard Adams, John Zalcberg, Carsten Bokemeyer, Takayuki Yoshino, Qian Shi, Alan P. Venook, Levi Pederson, Miriam Koopman, Niall C. Tebbutt, Heshan Liu
Background Unplanned subgroup analyses from several studies have suggested primary tumor sidedness (PTS) as a potential prognostic and predictive parameter in metastatic colorectal cancer (mCRC). We aimed to investigate the impact of PTS on outcomes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2557db80e3d7b8e1034562b8847a27e5
Autor:
Zhaohui Jin, Jesse G. Dixon, Joleen M. Hubbard, Cathy Eng, Christopher Hanyoung Lieu, Jack Fiskum, Leonard B. Saltz, Herbert I. Hurwitz, Alan P. Venook, Hans-Joachim Schmoll, Charles S. Fuchs, J. Randolph Randolph Hecht, Chiara Cremolini, Eduardo Diaz-Rubio, Cornelis J. A. Punt, Niall C. Tebbutt, Volker Heinemann, Takayuki Yoshino, Aimery De Gramont, Qian Shi
Publikováno v:
Journal of Clinical Oncology. 40:101-101
101 Background: Colorectal cancer (CRC) incidence and mortality have decreased since the 1970s, but the incidence in young adults (20-49 years, named early-onset CRC, eoCRC) has been increasing. eoCRC patients with metastatic disease are treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caac5638c8b45458327e3195c2452203
https://doi.org/10.1200/jco.2022.40.4_suppl.101
https://doi.org/10.1200/jco.2022.40.4_suppl.101
Autor:
Jesus Garcia Foncillas, Margarita Feyjoo, Eduardo Diaz Rubio, Ana Gómez, Carlos Camps, Rafael López, Enrique Aranda, Paloma Gómez Solana, Juan Jesús Cruz, Vicente Guillem, Ilse Lugo, Manuel Constenla, Pedro Gascon, Alfredo Carrato, Elena Ruiz, Antonio Antón
Publikováno v:
Journal of Clinical Oncology. 37:e18295-e18295
e18295 Background: To develop an improvement project, the Lung Cancer Unit of Ramón y Cajal Hospital (Madrid) analyzed 45 patients treated with immunotherapy in 2017 and detected that 55% presented moderate-to-severe Adverse Events (AEs). Consequent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4398b15e7953b97b5081a50ec313e18b
https://doi.org/10.1200/jco.2019.37.15_suppl.e18295
https://doi.org/10.1200/jco.2019.37.15_suppl.e18295
Autor:
Atocha Romero, Xiaping He, Manuel Arroyo Fernández, José Ángel García Sáenz, Eduardo Diaz Rubio, Miguel Martín, Belén Oliva, Miguel de la Hoya, Charles M. Perou, Trinidad Caldés Llopis, Maggie C.U. Cheang, José Antonio López García-Asenjo
Publikováno v:
The American Journal of Pathology. 178:1453-1460
Anthracyclines are frequently used for the treatment of breast cancer and topoisomerase II alpha (TOP2A) is considered to be the molecular target. Numerous studies have evaluated the predictive value of TOP2A using different methodological approaches
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a904388a8a23dcf96be1a2f203095fea
https://doi.org/10.1016/j.ajpath.2010.12.042
https://doi.org/10.1016/j.ajpath.2010.12.042
Autor:
Rafael López, Margarita Feyjoo, Juan José Reina, Carlos Camps, Eduardo Diaz Rubio, Fernando Caballero, Diana Monge, Alfredo Carrato, Vicente Guillem, Jesús García-Foncillas, Enrique Aranda
Publikováno v:
Journal of Clinical Oncology. 36:e18785-e18785
e18785Background: Breakthrough cancer pain (BTcP) is a common condition, but its management may be often suboptimal. We aim to determine if physician’s perception of the management and characterist...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75c67c2fa9a3592e08119e126363418d
https://doi.org/10.1200/jco.2018.36.15_suppl.e18785
https://doi.org/10.1200/jco.2018.36.15_suppl.e18785